Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts assign Arrowhead a consensus rating of Moderate Buy from 11 firms (6 buy, 4 hold, 1 strong buy) with an average 12‑month target of $81.67, and several banks (BofA, Goldman, Morgan Stanley, RBC) recently raised targets into the $80–85 range.
• In the latest quarter ARWR reported $0.22 EPS, missing the $0.60 consensus, but revenue beat at $264.0M and surged over 10,000% year‑over‑year.
• Insiders have sold 495,836 shares worth roughly $32.76M in the past 90 days (insiders still own 3.6%) while institutional investors hold 62.61% of the stock.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eleven ratings firms that are currently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $81.6667.

Several equities analysts have recently weighed in on ARWR shares. Bank of America raised their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a "buy" rating in a report on Tuesday, December 9th. The Goldman Sachs Group upped their price target on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, January 7th. Morgan Stanley increased their price objective on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an "equal weight" rating in a research report on Wednesday, January 7th. Royal Bank Of Canada raised their price objective on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an "outperform" rating in a research note on Thursday, December 11th. Finally, Weiss Ratings raised shares of Arrowhead Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, February 6th.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $58.10 on Thursday. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. The stock has a market cap of $8.14 billion, a P/E ratio of 37.97 and a beta of 1.23. The business's 50 day moving average price is $64.95 and its 200-day moving average price is $50.88. Arrowhead Pharmaceuticals has a 52 week low of $9.57 and a 52 week high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts' consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The company had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. During the same period last year, the business earned ($1.39) EPS. The firm's quarterly revenue was up 10461.3% on a year-over-year basis. Equities research analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Mauro Ferrari sold 7,530 shares of the business's stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $70.00, for a total value of $527,100.00. Following the completion of the transaction, the director directly owned 69,053 shares in the company, valued at $4,833,710. The trade was a 9.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Adeoye Y. Olukotun sold 10,000 shares of the stock in a transaction on Friday, December 19th. The shares were sold at an average price of $67.66, for a total value of $676,600.00. Following the sale, the director owned 33,600 shares in the company, valued at approximately $2,273,376. This represents a 22.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 495,836 shares of company stock valued at $32,759,810 over the last ninety days. Corporate insiders own 3.60% of the company's stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently bought and sold shares of ARWR. Tsfg LLC purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter worth about $25,000. iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $29,000. First Horizon Corp bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth approximately $32,000. Virtus Advisers LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth approximately $34,000. Finally, Salomon & Ludwin LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at approximately $34,000. 62.61% of the stock is currently owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.